1.	A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FDA IND 100712, NCT00611208
2.	Interleukin 13 PE for Adults With Advanced Cancers Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 130046, 13-C-0046, NCT01766635
3.	LMB-2 to Treat Hairy Cell Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 060150, 06-C-0150, NCI-06-C-0150, NCI-P6760, 7834, NCI-7834, NCT00337311, NCT00321555
4.	Ovarian Dendritic Cell Vaccine Trial Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 200541, NCT00703105
5.	Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090025, 09-C-0025, NCT00924170
6.	A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Imtox 25, NCT01378871
7.	IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IL13PEI-106, CCF-IRB-7161, NEOPHARM-IL13PEI-106, NCT00089427
8.	Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 17 Sponsor: Other Protocol IDs: CDR0000495296, AECM-CCI-2005-536, AECM-CCI-05-428, AECM-MMC-05-10-265C, NCT00450944
9.	Phase I Study of Anti-CD19/CD22 Bispecific Ligand-Directed Toxin DT2219ARL in Patients With Relapsed or Refractory CD19(+) and CD22(+) B-Lineage Leukemia or Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 12 Sponsor: NCI Protocol IDs: S-WHITE-81714, 81714, DT2219ARL, IRB#00000706, NCT00889408
10.	An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma Phase: Phase I Type: Treatment Status: Active Age: Under 18 Sponsor: NINDS Protocol IDs: 090117, 09-N-0117, NCT00880061
11.	Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAT-8015-1003, NCI-07-C-0200, 07-C-0200, NCI-P7118, NCT00522483, NCT00515892
12.	SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110160, 11-C-0160, NCT01362790
13.	Phase 1 Study of Combotox With Cytarabine in Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia (ALL) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 11-04-146, NCT01408160